You are about to leave the Clinical Value website now.
A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC,…
Read Article
Liver cancer known also as the silent killer, chronic liver disease is big, complex and accelerating. Driven by viral infection, diet and lifestyle, 1.5 billion people worldwide are in jeopardy. Of these, 80% of new cases and 72% of total deaths occur in Asia alone.
Our educational hub on liver cancer diagnostic insights including disease understanding, diagnostic testing, therapeutic treatments to monitoring – a new era of partnership and innovation provides the opportunity to improve the lives of millions of people around the world.
In this white paper, insights on the liver ecosystem are uncovered, with the intention of facilitating action among various stakeholders to reduce liver cancer incidence and…
READ MORE
In this whitepaper, HCC surveillance programs in Asia were analysed. The learnings from well established HCC surveillance programs, as well as the challenges in areas that…
READ MORE
This white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker…
READ MORE
Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…
READ MORE
This study aimed to investigate the role of serum PIVKA-II and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission following NA…
READ MORE
This meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.…
READ MORE
The purpose of this study is to evaluate the prognostic values of serum markers in HCC, with retrospective data. Li B, Liu A, Wen Y, Yang…
READ MORE
This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients. Xu F, Zhang L, He W,…
READ MORE
The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal…
READ MORE
This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC. Bhatti ABHH, Naz K, Abbas G, Khan NY,…
READ MORE
This article aims to clarify the diagnostic value of DCP (PIVKA-II) and AFP in patients with different risk of HCC development (etiology, ethnicity, and various stages…
READ MORE
This study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically. Pang BY, Leng…
READ MORE
This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…
READ MORE
This study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its…
READ MORE
Society guidelines differ in their recommendations for surveillance to detect early-stage hepatocellular carcinoma (HCC) in patients with cirrhosis. This study compared the performance of surveillance imaging,…
READ MORE
This study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in…
READ MORE
This study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B…
READ MORE
PIVKA-II has been extensively studied as a biomarker in HCC. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of…
READ MORE
This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its…
READ MORE
Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This…
READ MORE
This study systematically evaluates biomarkers mentioned in international guidelines and peer-reviewed literature for HCC surveillance and diagnosis, in order to identify combinations of biomarkers that display…
READ MORE
This study evaluates the clinical performance of the new Elecsys PIVKA-II immunoassay and the previously launched Elecsys AFP assay (Roche Diagnostics) to aid in the diagnosis…
READ MORE
Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify…
READ MORE
This study evaluates the analytical performance of the Elecsys PIVKA-II immunoassay to aid in HCC diagnosis, establish method-specific reference ranges in healthy individuals, and perform a…
READ MORE
In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem,…
READ MORE
In this video, Prof Henry LY Chan, Deputy Chief Manager at Union Hospital Hong Kong, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…
READ MORE
A/Prof Simone Strasser recently published an independent commentary in the Australian Medical Research and Journal "Research Review", covering at length topics such as non-alcoholic liver disease…
READ MORE
In this video, Prof Ming-Lung Yu, Chair Professor of Hepatology at Kaohsiung University Medical Hospital, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…
READ MORE
In this video, Dr Bao Toan Nguyen from MEDIC-LAB Ho Chi Minh discusses how PIVKA-II can complement AFP in assisting clinicians in the early detection and…
READ MORE
In this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…
READ MORE
Liver disease is a serious public health issue in Taiwan. The Liver Disease Prevention and Treatment Research Foundation, Taiwan, is one of Asia’s most active and…
READ MORE
Japan is a global leader in hepatocellular carcinoma (HCC) surveillance, with an effective programme that enables early-stage carcinomas detection. Yet unmet needs continue to affect the…
READ MORE
More than 27,000 patients in Thailand are found to have liver cancer each year, making it the most-frequently diagnosed cancer in the country. With emerging risk…
READ MORE
Punjab is one of Pakistan’s largest provinces and has a particularly high HCV prevalence rate of roughly 9%, compared to 5.4% for Pakistan’s total population. Hear…
READ MORE
In line with the WHO Essential Diagnostics List (EDL) and Lancet Commission efforts, the Asia Pacific Medical Technology Association and its members recently came together to…
READ MORE
In 2019, Pakistan announced a nationwide programme to scale up HCV prevention, testing and treatment. Hear from gastroenterologist Dr Huma Qureshi, a key figure in Pakistan’s…
READ MORE
An estimated 71 million people around the world are chronically infected with hepatitis C virus (HCV), with a large proportion currently being undiagnosed or diagnosed late.…
READ MORE
In 2018, the world’s largest HCV screening campaign was initiated in Egypt. Within 7 months following its initiation, 49.5 million people were screened; and 2.2 million…
READ MORE
The province of Sindh has one of the world’s highest rates of HCV infection and bears the second highest disease burden of both HBV and HCV…
READ MORE
Pakistan has one of the world’s highest rates of HCV infection. It's no surprise that their healthcare systems face mounting pressure from HCV-related conditions. Learn from…
READ MORE
Hepatitis B is an important infectious disease problem in the APAC region. Learn from Prof Henry Chan, director of the Center for Liver Health at Chinese…
READ MORE
This study aims to establish and train the algorithm coefficients, and clinically validate the performance of the GAAD algorithm in differentiating HCC and benign chronic liver…
READ MORE
In this white paper, insights on the liver ecosystem are uncovered, with the intention of facilitating action among various stakeholders to reduce liver cancer incidence and…
READ MOREIn this whitepaper, HCC surveillance programs in Asia were analysed. The learnings from well established HCC surveillance programs, as well as the challenges in areas that…
READ MOREThis study aimed to investigate the role of serum PIVKA-II and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission following NA…
READ MOREThis meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.…
READ MOREThe purpose of this study is to evaluate the prognostic values of serum markers in HCC, with retrospective data. Li B, Liu A, Wen Y, Yang…
READ MOREThis study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients. Xu F, Zhang L, He W,…
READ MORE
This systematic review and meta-analysis of cohort studies of patients with cirrhosis aimed to evaluate the benefit and harms of HCC surveillance in patients with cirrhosis.…
READ MOREThe aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal…
READ MORE
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease.
READ MOREThis study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC. Bhatti ABHH, Naz K, Abbas G, Khan NY,…
READ MOREA panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and…
READ MOREThis article aims to clarify the diagnostic value of DCP (PIVKA-II) and AFP in patients with different risk of HCC development (etiology, ethnicity, and various stages…
READ MOREThis study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically. Pang BY, Leng…
READ MORE
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MOREThis review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…
READ MORE
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…
READ MORE
These latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.…
READ MOREThis study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its…
READ MOREThis white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker…
READ MORE
Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition), additional high-quality evidence has emerged with relevance to the diagnosis, staging,…
READ MORE
The 4th version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, and published in October 2017 in Japanese. New…
READ MORESociety guidelines differ in their recommendations for surveillance to detect early-stage hepatocellular carcinoma (HCC) in patients with cirrhosis. This study compared the performance of surveillance imaging,…
READ MORE
HCC diagnosis can be particularly challenging in some cases and the obtained results seem ambiguous, resulting in a long-term and delayed diagnostic process.This paper presents three…
READ MOREThis study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in…
READ MOREThis study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B…
READ MORE
This review article provides a comprehensive overview of the indications and rationale for HCC surveillance, currently available surveillance methods and their utilization, effectiveness, and limitations, as…
READ MOREPIVKA-II has been extensively studied as a biomarker in HCC. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of…
READ MOREThis study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its…
READ MORE
The performance of Elecsys® GAAD score, which includes the parameters of gender, age, alpha-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonists-II (PIVKA-II) in…
READ MOREProthrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This…
READ MORE
The Elecsys® GAAD algorithm combines quantitative measurements of Elecsys PIVKA-II assay and Elecsys AFP assay, plus age and gender to generate a semi-quantitative result. This study…
READ MOREThis study systematically evaluates biomarkers mentioned in international guidelines and peer-reviewed literature for HCC surveillance and diagnosis, in order to identify combinations of biomarkers that display…
READ MOREThis study evaluates the clinical performance of the new Elecsys PIVKA-II immunoassay and the previously launched Elecsys AFP assay (Roche Diagnostics) to aid in the diagnosis…
READ MOREProthrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify…
READ MOREDiagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…
READ MOREThis study evaluates the analytical performance of the Elecsys PIVKA-II immunoassay to aid in HCC diagnosis, establish method-specific reference ranges in healthy individuals, and perform a…
READ MORE
This study compared the clinical performance of the Elecsys GALAD (gender [sex], age, alpha-fetoprotein [AFP] Lens culinaris agglutinin-reactive fraction of AFP [AFP-L3] and protein-induced by vitamin…
READ MORE
Watch the APASL 2024 seminar recording to hear experts share key updates on curative approaches to HCC management, treatment apporaches for BCLC-B uHCC, and real world…
READ MORE
Missed the satellite symposium session from ESMO Asia 2023? Access the webcast recording here.
READ MORE
Watch the APASL 2023 symposium recording to hear experts share key updates on HCC surveillance, diagnosis, uHCC management and adj HCC systemic treatment.
READ MORE
This presentation has 2 parts. In the first part of this presentation, Prof. Nobuharu Tamaki discusses the diagnostic utility of PIVKA-II in HCC, and the potential…
READ MORE
Detection of HCC at early stages remains a challenge, with less than 20% of patients being diagnosed at an early stage, when they can benefit from…
READ MORE
In this presentation, Prof. Ming Lung Yu discusses the results of his study, which aims to address the diagnostic accuracy of HCC using Elecsys GAAD algorithmic…
READ MORE
In this presentation, Prof. Do Young Kim reviews the results of the APAC expert consensus study on the utilization of PIVKA-II in the surveillance and monitoring…
READ MORE
The liver cancer landscape has been undergoing a period of rapid transformation. From early detection of HCC using new biomarkers, to new immunotherapy treatment options. Watch…
READ MORE
Join the webinar to hear speakers Prof. Henry Chan and Prof. Hui Chuan Sun as they discuss the use of PIVKA-II and GAAD score as promising…
READ MORE
Join the webinar to hear speakers Prof. Henry Chan, and Assoc. Prof. Teerha Piratvisuth as they discuss the clinical usefulness of PIVKA-II in HCC surveillance, as…
READ MORE
Mr Yan was diagnosed with hepatocellular carcinoma (HCC) in 2018. He was a healthy, active person as a competitive skier, and his diagnosis was completely unexpected.…
READ MORE
Chronic liver disease (CLD) is on the rise. CLD can progress to Hepatocellular Carcinoma (HCC), a type of liver cancer. What are the risk factors for…
READ MORE
How did Taiwan halve the incidence of hepatocellular carcinoma (HCC) in a decade? HCC is the primary form of liver cancer, with 72% of cases diagnosed…
READ MORE
Do you know what can cause hepatocellular carcinoma, the primary form of liver cancer? In Asia, contaminated food has historically been linked with the disease and…
READ MORE
Hepatocellular carcinoma numbers continue to rise globally, due to major risk factors such as Hepatitis B and C, and fatty liver disease. Hear Liver Patients International’s…
READ MORE
Millions of people are living with chronic liver disease. Can the link between chronic liver disease and liver cancer be broken through partnership?
READ MORE